Drug intelligence / Profile preview

QA108

Development stage: Phase 3
Lead developer: Zhuhai Qi Microorganism Technology
Administration: Oral

Overview

QA108 is an investigational herbal medicine developed for the treatment of intermediate age-related macular degeneration (AMD), specifically targeting the "Yin deficiency and Yang hyperactivity" subtype as classified in traditional Chinese medicine. The product is formulated as granules and has been evaluated in randomized, double-blind, placebo-controlled multicenter clinical trials. Its precise mechanism of action remains unknown or uncharacterized in Western pharmacological terms. The drug is being developed by Zhuhai Qi Microorganism Technology Co., Ltd., also referenced as Smilebiotek Zhuhai Limited[1][2][3][4]. As of May 2025, its highest global development status is Phase 3 for age-related macular degeneration[1].

Other names: QA108 granulesQA-108 granulesQA 108 granules

Beyond the preview

Go deeper on QA108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QA108.

Explore the full profile